NTBL
NASDAQNotable Labs Ltd.
$0.25-0.10 (-29.15%)
News25/Ratings1
Latest news
25 items- SECNotable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Notable Labs, Ltd. (0001603207) (Filer)
- SECNotable Labs Ltd. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update8-K - Notable Labs, Ltd. (0001603207) (Filer)
- INSIDERNew insider Zagger Kaile A. claimed no ownership of stock in the company (SEC Form 3)3 - Notable Labs, Ltd. (0001603207) (Issuer)
- ANALYSTNotable Labs downgraded by JMP SecuritiesJMP Securities downgraded Notable Labs from Mkt Outperform to Mkt Perform
- SECNotable Labs Ltd. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities8-K - Notable Labs, Ltd. (0001603207) (Filer)
- SECNotable Labs Ltd. filed SEC Form 8-K: Leadership Update8-K - Notable Labs, Ltd. (0001603207) (Filer)
- SECAmendment: SEC Form S-1/A filed by Notable Labs Ltd.S-1/A - Notable Labs, Ltd. (0001603207) (Filer)
- PRNotable Labs to Present Data on September 4th at SOHO 2024Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data from preclinical studies evaluating volasertib for acute myeloid leukemia (AML) at the twelfth annual meeting of the Society for Hematologic Oncology (SOHO 2024), b
- SECAmendment: SEC Form S-1/A filed by Notable Labs Ltd.S-1/A - Notable Labs, Ltd. (0001603207) (Filer)
- SECNotable Labs Ltd. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Notable Labs, Ltd. (0001603207) (Filer)
- PRNotable Labs Announces CEO TransitionThomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T
- SECSEC Form 10-Q filed by Notable Labs Ltd.10-Q - Notable Labs, Ltd. (0001603207) (Filer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Notable Labs Ltd.SC 13D/A - Notable Labs, Ltd. (0001603207) (Subject)
- SECNotable Labs Ltd. filed SEC Form 8-K: Regulation FD Disclosure8-K - Notable Labs, Ltd. (0001603207) (Filer)
- NEWSNotable Labs shares are trading lower. The company announced progress for its Phase 2 volasertib program.
- SECNotable Labs Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Notable Labs, Ltd. (0001603207) (Filer)
- NEWSNotable Labs Announced Progress For The Phase 2 Volasertib Program Following Receipt Of "clearance To Proceed" From The FDA And Agreement On The Dosing Plan For Its Phase 2 Clinical Trial
- PRNotable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 StudyFOSTER CITY, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of "Clearance to Proceed" from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming mo
- SECNotable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Notable Labs, Ltd. (0001603207) (Filer)
- SECAmendment: SEC Form S-1/A filed by Notable Labs Ltd.S-1/A - Notable Labs, Ltd. (0001603207) (Filer)
- SECSEC Form S-1 filed by Notable Labs Ltd.S-1 - Notable Labs, Ltd. (0001603207) (Filer)
- SECNotable Labs Ltd. filed SEC Form 8-K: Regulation FD Disclosure8-K - Notable Labs, Ltd. (0001603207) (Filer)
- NEWSChardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $5Chardan Capital analyst Keay Nakae maintains Notable Labs (NASDAQ:NTBL) with a Buy and lowers the price target from $7 to $5.
- SECSEC Form 10-Q filed by Notable Labs Ltd.10-Q - Notable Labs, Ltd. (0001603207) (Filer)
- INSIDERPatsi Tuomo was granted 65,247 units of Ordinary Shares (SEC Form 4)4 - Notable Labs, Ltd. (0001603207) (Issuer)